Beirne Wealth Consulting Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Beirne Wealth Consulting Services’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,048	Closed	-$410K	–	223
2025 Q3	$410K	Buy	+1,048	New	+$438K	0.1%	122
2021 Q1	–	Sell	-1,163	Closed	-$275K	–	171
2020 Q4	$275K	Buy	1,163 +115	+11%	+$26.4K	0.14%	117
2020 Q3	$285K	Buy	+1,048	New	+$289K	0.17%	100
2019 Q3	–	Sell	-1,154	Closed	-$212K	–	140
2019 Q2	$212K	Sell	1,154 -958	-45%	-$167K	0.19%	120
2019 Q1	$389K	Sell	2,112 -355	-14%	-$65.6K	0.31%	107
2018 Q4	$409K	Buy	+2,467	New	+$427K	0.35%	94

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Beirne Wealth Consulting Services's VRTX Position: Q4 2025 in Review

Beirne Wealth Consulting Services sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 1,048 shares — an estimated $410K sold.

Beirne Wealth Consulting Services first reported a position in VRTX in Q4 2018 and held it in 6 quarters. The position peaked at $410K in Q3 2025. 1,669 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Beirne Wealth Consulting Services reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Beirne Wealth Consulting Services sold 1,048 Vertex Pharmaceuticals shares in Q4 2025, an estimated $410K.
Beirne Wealth Consulting Services first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 6 quarters.
Beirne Wealth Consulting Services's Vertex Pharmaceuticals position peaked at $410K in Q3 2025.
1,669 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Beirne Wealth Consulting Services's 13F filing for Q4 2025, filed 29 Jan 2026.